Moon Rebecca J, D'Angelo Stefania, Curtis Elizabeth M, Ward Kate A, Godfrey Keith M, Cooper Cyrus, Harvey Nicholas C
MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK.
Paediatric Endocrinology, Southampton Children's Hospital, University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK.
Osteoporos Int. 2025 Jun 23. doi: 10.1007/s00198-025-07568-0.
The effect of pregnancy vitamin D supplementation on bone mineral density (BMD) in the mother immediately after delivery and at 4 years after delivery was assessed in a randomised placebo-controlled trial. The mothers' BMD did not differ between the two intervention groups.
Vitamin D supplementation during pregnancy has positive effects on the offspring's bone development and bone mineral density (BMD) in childhood, but there are limited data on the effects on the mother's skeleton. We assessed this in a post hoc follow-up of a randomised trial.
MAVIDOS was a randomised placebo-controlled trial of 1000 IU/day cholecalciferol from 14 to 17 weeks gestation until delivery. Participants were invited to have a dual-energy X-ray absorptiometry (DXA) scan of the whole body, lumbar spine (LS) and left hip within 2 weeks after delivery and again 4 years after delivery. BMD was compared between the cholecalciferol and placebo groups; in women with DXA at both time points, the effect of cholecalciferol was assessed using mixed effects modelling to account for repeated measures.
Four hundred one and 443 participants had a DXA within 2 weeks after delivery and at a mean of 4.1 years after delivery, respectively. Cholecalciferol supplementation increased serum 25-hydroxyvitamin D status in late pregnancy compared to placebo. BMD at all sites was similar between the two randomisation groups at both time points (p > 0.05 for all). Two hundred sixty-three participants had a DXA at both birth and 4 years. BMD increased between 1 and 6% depending on the site from within 2 weeks to 4 years after delivery. This was similar between randomisation groups. The pregnancy cholecalciferol had no effect on BMD at 4 years in repeated measures modelling.
Despite previously demonstrated benefits for the offspring skeleton in this trial, maternal BMD did not differ in the short or medium term in women randomised to 1000 IU/day vitamin D or placebo.
在一项随机安慰剂对照试验中，评估了孕期补充维生素D对母亲产后即刻及产后4年骨密度（BMD）的影响。两个干预组母亲的骨密度无差异。
孕期补充维生素D对后代骨骼发育及儿童期骨密度（BMD）有积极影响，但关于对母亲骨骼影响的数据有限。我们在一项随机试验的事后随访中对此进行了评估。
MAVIDOS是一项随机安慰剂对照试验，从妊娠14至17周直至分娩，每天补充1000 IU胆钙化醇。邀请参与者在产后2周内及产后4年进行全身、腰椎（LS）和左髋部的双能X线吸收法（DXA）扫描。比较胆钙化醇组和安慰剂组的骨密度；在两个时间点均进行DXA检查的女性中，使用混合效应模型评估胆钙化醇的效果，以考虑重复测量。
分别有401名和443名参与者在产后2周内及产后平均4.1年进行了DXA检查。与安慰剂相比，补充胆钙化醇可提高妊娠晚期血清25 - 羟基维生素D水平。两个随机分组组在两个时间点所有部位的骨密度均相似（所有p>0.05）。263名参与者在出生时和4岁时均进行了DXA检查。从产后2周到4年，根据部位不同，骨密度增加了1%至6%。随机分组组之间情况相似。在重复测量模型中，孕期补充胆钙化醇对4年时的骨密度无影响。
尽管在该试验中先前已证明对后代骨骼有益，但随机分配至每天1000 IU维生素D或安慰剂组中的女性，其母亲的骨密度在短期或中期并无差异。
